drugset / Trial / NCT03093272
A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying a combination of drugs as a possible treatment for castration-resistant prostate cancer. The interventions involved in this study are: * Docetaxel (a type of chemotherapy) * Apalutamide (the study medication, also known as ARN-509) * Prednisone (a corticosteroid given to prevent reactions to docetaxel). * Leuprolide acetate (also known as Lupron, a GnRH agonist or similar drug which is standard of care, causes chemical castration which greatly lowers the level of testosterone in the body)
Timeline
- Start
- 2017-06-23
- Primary completion
- 2019-05-16
- Completion
- 2019-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apalutamide | Small molecule | 60 mg | Oral |
| Subject | Docetaxel | Small molecule | — | Intravenous |
| Background | Leuprolide | Other / unclassified | — | — |
| Background | Prednisone | Other / unclassified | — | Oral |